New shot shows promise for fatty liver disease in early trial
Disease control
Completed
This study tested a drug called BOS-580 (efimosfermin) in 231 obese adults with or at risk for NASH, a serious fatty liver disease. Participants received either the drug or a placebo as a shot under the skin. The main goal was to check safety and side effects. The trial is now co…
Phase: PHASE2 • Sponsor: Boston Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC